CD274 and Merkel cell skin cancer: Immunotherapy with PD-L1/PD-1 monoclonal antibodies (e.g., pembrolizumab, nivolumab, avelumab) is being used in advanced MCC and has been showing a promising potential for long-term disease control and improved survival.